Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Shock, Cardiogenic | 22 | 2024 | 709 | 5.330 |
Why?
|
Coronary Care Units | 15 | 2024 | 235 | 2.770 |
Why?
|
Heart Failure | 24 | 2024 | 11671 | 1.940 |
Why?
|
Glucosides | 5 | 2024 | 512 | 1.760 |
Why?
|
Benzhydryl Compounds | 6 | 2024 | 916 | 1.450 |
Why?
|
Cardiology | 10 | 2024 | 1656 | 1.450 |
Why?
|
Myocardial Infarction | 11 | 2023 | 11461 | 1.240 |
Why?
|
Cardiopulmonary Resuscitation | 5 | 2022 | 993 | 1.150 |
Why?
|
Hemorrhage | 6 | 2022 | 3424 | 1.100 |
Why?
|
Foramen Ovale, Patent | 2 | 2019 | 208 | 1.070 |
Why?
|
Tricuspid Valve | 2 | 2019 | 410 | 1.040 |
Why?
|
Hospital Mortality | 19 | 2024 | 5293 | 1.030 |
Why?
|
Biphenyl Compounds | 2 | 2021 | 1007 | 1.010 |
Why?
|
Heart-Assist Devices | 5 | 2023 | 1287 | 1.010 |
Why?
|
Acute Coronary Syndrome | 6 | 2023 | 2190 | 0.990 |
Why?
|
Tricuspid Valve Insufficiency | 2 | 2019 | 353 | 0.970 |
Why?
|
Critical Care | 16 | 2024 | 2697 | 0.940 |
Why?
|
Angiotensin Receptor Antagonists | 2 | 2021 | 1039 | 0.900 |
Why?
|
Intra-Aortic Balloon Pumping | 4 | 2024 | 223 | 0.860 |
Why?
|
Pyridines | 3 | 2021 | 2875 | 0.830 |
Why?
|
Thiazoles | 2 | 2021 | 1517 | 0.830 |
Why?
|
Hemodynamics | 3 | 2023 | 4160 | 0.810 |
Why?
|
Ventricular Dysfunction, Left | 3 | 2023 | 2118 | 0.810 |
Why?
|
Registries | 18 | 2024 | 8225 | 0.800 |
Why?
|
Atrial Fibrillation | 7 | 2023 | 5127 | 0.800 |
Why?
|
Embolism | 3 | 2021 | 399 | 0.790 |
Why?
|
Heart Massage | 2 | 2019 | 32 | 0.740 |
Why?
|
Intensive Care Units | 12 | 2024 | 3744 | 0.740 |
Why?
|
Dyspnea | 2 | 2019 | 1347 | 0.740 |
Why?
|
Calgranulin A | 1 | 2021 | 80 | 0.720 |
Why?
|
Calgranulin B | 1 | 2021 | 86 | 0.720 |
Why?
|
Out-of-Hospital Cardiac Arrest | 3 | 2022 | 339 | 0.710 |
Why?
|
Diabetes Mellitus, Type 2 | 7 | 2024 | 12149 | 0.690 |
Why?
|
Thromboembolism | 3 | 2021 | 995 | 0.680 |
Why?
|
Stroke Volume | 5 | 2023 | 5496 | 0.680 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2019 | 1551 | 0.680 |
Why?
|
Proteomics | 2 | 2024 | 3848 | 0.650 |
Why?
|
Hospitals, Special | 1 | 2019 | 91 | 0.640 |
Why?
|
Natriuretic Peptide, Brain | 6 | 2024 | 1723 | 0.620 |
Why?
|
P-Selectin | 1 | 2021 | 597 | 0.620 |
Why?
|
Coronary Restenosis | 1 | 2021 | 396 | 0.610 |
Why?
|
Diabetic Cardiomyopathies | 1 | 2019 | 90 | 0.610 |
Why?
|
Personnel, Hospital | 1 | 2020 | 285 | 0.590 |
Why?
|
Cardiovascular Diseases | 9 | 2023 | 15502 | 0.560 |
Why?
|
Secondary Prevention | 2 | 2021 | 1475 | 0.560 |
Why?
|
Risk Assessment | 16 | 2024 | 23996 | 0.550 |
Why?
|
Troponin I | 1 | 2021 | 651 | 0.540 |
Why?
|
Hospitalization | 9 | 2024 | 10721 | 0.540 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 1 | 2017 | 92 | 0.530 |
Why?
|
Cardiovascular System | 1 | 2023 | 834 | 0.510 |
Why?
|
Guidelines as Topic | 2 | 2019 | 1386 | 0.490 |
Why?
|
Consensus | 1 | 2024 | 3124 | 0.480 |
Why?
|
Burnout, Professional | 2 | 2020 | 704 | 0.460 |
Why?
|
Patient Care | 1 | 2019 | 622 | 0.450 |
Why?
|
Atherosclerosis | 4 | 2023 | 3407 | 0.450 |
Why?
|
Workload | 1 | 2019 | 844 | 0.440 |
Why?
|
Lactones | 1 | 2016 | 317 | 0.430 |
Why?
|
Stroke | 5 | 2023 | 9758 | 0.420 |
Why?
|
North America | 6 | 2024 | 1276 | 0.410 |
Why?
|
Humans | 86 | 2024 | 761596 | 0.400 |
Why?
|
Ventricular Function, Left | 3 | 2021 | 3879 | 0.400 |
Why?
|
Occupational Diseases | 1 | 2020 | 1490 | 0.390 |
Why?
|
Extracorporeal Membrane Oxygenation | 2 | 2020 | 1462 | 0.380 |
Why?
|
Immunity, Cellular | 1 | 2017 | 1560 | 0.370 |
Why?
|
Thoracic Surgical Procedures | 1 | 2015 | 350 | 0.370 |
Why?
|
Education, Medical, Graduate | 4 | 2024 | 2373 | 0.370 |
Why?
|
Healthcare Disparities | 3 | 2024 | 3358 | 0.360 |
Why?
|
Thrombosis | 2 | 2022 | 2942 | 0.360 |
Why?
|
Internship and Residency | 6 | 2024 | 5882 | 0.340 |
Why?
|
Troponin | 3 | 2023 | 502 | 0.330 |
Why?
|
Myocarditis | 1 | 2017 | 788 | 0.330 |
Why?
|
Decision Support Techniques | 1 | 2019 | 1998 | 0.330 |
Why?
|
Pneumonia, Pneumocystis | 2 | 2020 | 242 | 0.320 |
Why?
|
Aged | 27 | 2024 | 169310 | 0.310 |
Why?
|
Defibrillators, Implantable | 1 | 2018 | 1490 | 0.310 |
Why?
|
Heart Arrest | 4 | 2020 | 1514 | 0.300 |
Why?
|
Middle Aged | 29 | 2024 | 220921 | 0.300 |
Why?
|
Anticoagulants | 3 | 2022 | 4812 | 0.300 |
Why?
|
Female | 40 | 2024 | 392705 | 0.270 |
Why?
|
Catheters, Indwelling | 2 | 2019 | 426 | 0.270 |
Why?
|
Male | 37 | 2024 | 360846 | 0.260 |
Why?
|
Risk Factors | 17 | 2024 | 74213 | 0.260 |
Why?
|
Platelet Aggregation Inhibitors | 3 | 2022 | 2751 | 0.260 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3086 | 0.250 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3206 | 0.250 |
Why?
|
Emergency Medical Services | 2 | 2019 | 1923 | 0.250 |
Why?
|
Critical Illness | 4 | 2022 | 2723 | 0.250 |
Why?
|
Pulmonary Artery | 2 | 2024 | 1927 | 0.240 |
Why?
|
Drug Combinations | 2 | 2021 | 2048 | 0.230 |
Why?
|
Myocardium | 1 | 2017 | 4725 | 0.230 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 1516 | 0.220 |
Why?
|
Patient Admission | 3 | 2019 | 1367 | 0.220 |
Why?
|
Risk | 3 | 2021 | 9610 | 0.220 |
Why?
|
Pulmonary Wedge Pressure | 1 | 2024 | 273 | 0.210 |
Why?
|
Lactates | 1 | 2023 | 405 | 0.210 |
Why?
|
Phosphatidylcholine-Sterol O-Acyltransferase | 1 | 2022 | 33 | 0.210 |
Why?
|
Time Factors | 11 | 2024 | 39969 | 0.210 |
Why?
|
Anterior Wall Myocardial Infarction | 1 | 2022 | 42 | 0.200 |
Why?
|
Arrhythmias, Cardiac | 3 | 2023 | 2244 | 0.200 |
Why?
|
Lymphopenia | 2 | 2020 | 281 | 0.190 |
Why?
|
Electric Countershock | 2 | 2019 | 533 | 0.190 |
Why?
|
Treatment Outcome | 15 | 2024 | 64685 | 0.180 |
Why?
|
Hospital Rapid Response Team | 1 | 2021 | 54 | 0.180 |
Why?
|
Pandemics | 2 | 2020 | 8656 | 0.180 |
Why?
|
Respiration, Artificial | 1 | 2012 | 2630 | 0.180 |
Why?
|
Vascular Resistance | 1 | 2023 | 930 | 0.180 |
Why?
|
Chest Wall Oscillation | 1 | 2020 | 15 | 0.180 |
Why?
|
Prognosis | 9 | 2024 | 29629 | 0.170 |
Why?
|
Patients' Rooms | 1 | 2020 | 62 | 0.170 |
Why?
|
Protective Devices | 1 | 2020 | 72 | 0.170 |
Why?
|
T-Lymphocytes | 1 | 2017 | 10194 | 0.170 |
Why?
|
Platelet Function Tests | 1 | 2021 | 271 | 0.160 |
Why?
|
Peptide Fragments | 5 | 2024 | 5112 | 0.160 |
Why?
|
CD40 Ligand | 1 | 2021 | 522 | 0.160 |
Why?
|
Telecommunications | 1 | 2019 | 80 | 0.160 |
Why?
|
Enalapril | 1 | 2021 | 312 | 0.160 |
Why?
|
Job Satisfaction | 3 | 2015 | 544 | 0.160 |
Why?
|
Hypotension | 2 | 2024 | 879 | 0.160 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2023 | 2242 | 0.160 |
Why?
|
Ventricular Fibrillation | 3 | 2012 | 537 | 0.160 |
Why?
|
Hyperkalemia | 1 | 2021 | 233 | 0.160 |
Why?
|
Adamantane | 1 | 2019 | 148 | 0.150 |
Why?
|
Heart Valve Prosthesis Implantation | 2 | 2019 | 1553 | 0.150 |
Why?
|
Body Fluids | 1 | 2020 | 320 | 0.150 |
Why?
|
Advance Directives | 1 | 2020 | 249 | 0.150 |
Why?
|
Biomarkers, Pharmacological | 1 | 2019 | 161 | 0.150 |
Why?
|
Resuscitation Orders | 1 | 2020 | 270 | 0.150 |
Why?
|
Heart Transplantation | 2 | 2023 | 3233 | 0.150 |
Why?
|
Troponin T | 1 | 2023 | 780 | 0.150 |
Why?
|
Cardiotonic Agents | 1 | 2021 | 539 | 0.150 |
Why?
|
Cardiology Service, Hospital | 1 | 2019 | 239 | 0.150 |
Why?
|
Dipeptides | 1 | 2019 | 391 | 0.140 |
Why?
|
Aerosols | 1 | 2020 | 635 | 0.140 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 250 | 0.140 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2021 | 10212 | 0.140 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12463 | 0.140 |
Why?
|
Germany | 1 | 2019 | 875 | 0.140 |
Why?
|
Echocardiography | 2 | 2019 | 4989 | 0.130 |
Why?
|
Glomerular Filtration Rate | 2 | 2023 | 2178 | 0.130 |
Why?
|
Health Services Misuse | 1 | 2018 | 244 | 0.130 |
Why?
|
Epinephrine | 1 | 2019 | 792 | 0.130 |
Why?
|
Chest Pain | 1 | 2023 | 1091 | 0.130 |
Why?
|
Double-Blind Method | 3 | 2021 | 12341 | 0.130 |
Why?
|
Student Dropouts | 1 | 2015 | 27 | 0.130 |
Why?
|
Vasoconstrictor Agents | 1 | 2019 | 654 | 0.130 |
Why?
|
Pulmonary Embolism | 2 | 2019 | 2567 | 0.130 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 311 | 0.120 |
Why?
|
Disease Progression | 3 | 2023 | 13510 | 0.120 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2019 | 774 | 0.120 |
Why?
|
Renal Insufficiency | 1 | 2021 | 809 | 0.120 |
Why?
|
Leadership | 1 | 2024 | 1385 | 0.120 |
Why?
|
Health Status Disparities | 2 | 2024 | 1853 | 0.120 |
Why?
|
Drug Monitoring | 1 | 2021 | 962 | 0.120 |
Why?
|
Respiratory Insufficiency | 2 | 2020 | 1230 | 0.120 |
Why?
|
Carbon Dioxide | 1 | 2019 | 1147 | 0.120 |
Why?
|
Growth Differentiation Factor 15 | 3 | 2023 | 198 | 0.120 |
Why?
|
Electrocardiography | 3 | 2017 | 6377 | 0.120 |
Why?
|
Curriculum | 2 | 2024 | 3743 | 0.110 |
Why?
|
Cause of Death | 1 | 2024 | 3683 | 0.110 |
Why?
|
Venous Thrombosis | 1 | 2022 | 1303 | 0.100 |
Why?
|
Weight Loss | 1 | 2024 | 2684 | 0.100 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15843 | 0.100 |
Why?
|
Hospitals | 2 | 2023 | 3883 | 0.100 |
Why?
|
Fatal Outcome | 1 | 2017 | 1835 | 0.100 |
Why?
|
Scoliosis | 1 | 2019 | 741 | 0.100 |
Why?
|
Thrombolytic Therapy | 1 | 2021 | 2064 | 0.100 |
Why?
|
Intubation, Intratracheal | 1 | 2020 | 1333 | 0.100 |
Why?
|
Reproducibility of Results | 2 | 2021 | 20100 | 0.100 |
Why?
|
Tissue and Organ Procurement | 1 | 2020 | 962 | 0.100 |
Why?
|
Attitude of Health Personnel | 2 | 2020 | 3889 | 0.100 |
Why?
|
Clinical Trials as Topic | 2 | 2021 | 8002 | 0.100 |
Why?
|
Aortic Valve Stenosis | 1 | 2024 | 2001 | 0.090 |
Why?
|
General Surgery | 2 | 2015 | 1692 | 0.090 |
Why?
|
Comorbidity | 2 | 2023 | 10508 | 0.090 |
Why?
|
Career Choice | 2 | 2015 | 756 | 0.090 |
Why?
|
Platelet Aggregation | 1 | 2014 | 771 | 0.090 |
Why?
|
Foreign Medical Graduates | 1 | 2011 | 77 | 0.090 |
Why?
|
Survivors | 1 | 2021 | 2371 | 0.090 |
Why?
|
Niacin | 1 | 2011 | 118 | 0.090 |
Why?
|
Tissue Donors | 1 | 2020 | 2332 | 0.090 |
Why?
|
United States | 9 | 2024 | 72340 | 0.090 |
Why?
|
Pacemaker, Artificial | 1 | 2016 | 807 | 0.090 |
Why?
|
Death, Sudden, Cardiac | 1 | 2018 | 1555 | 0.090 |
Why?
|
Acute Disease | 1 | 2021 | 7237 | 0.090 |
Why?
|
Terminal Care | 1 | 2022 | 1761 | 0.090 |
Why?
|
Ticlopidine | 1 | 2014 | 730 | 0.080 |
Why?
|
Occupational Exposure | 1 | 2020 | 1813 | 0.080 |
Why?
|
Recovery of Function | 1 | 2019 | 2979 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2019 | 2759 | 0.080 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 3246 | 0.080 |
Why?
|
Hypoglycemic Agents | 1 | 2021 | 3085 | 0.080 |
Why?
|
Retrospective Studies | 9 | 2024 | 80647 | 0.080 |
Why?
|
Cardiac Surgical Procedures | 1 | 2024 | 3627 | 0.080 |
Why?
|
Survival Rate | 2 | 2020 | 12723 | 0.080 |
Why?
|
Telephone | 1 | 2012 | 627 | 0.080 |
Why?
|
Radiography | 1 | 2019 | 6965 | 0.070 |
Why?
|
Incidence | 3 | 2023 | 21355 | 0.070 |
Why?
|
Patient Education as Topic | 1 | 2018 | 2319 | 0.070 |
Why?
|
Sensitivity and Specificity | 1 | 2023 | 14665 | 0.070 |
Why?
|
Patient Selection | 1 | 2019 | 4244 | 0.070 |
Why?
|
Hypolipidemic Agents | 1 | 2011 | 609 | 0.070 |
Why?
|
Case-Control Studies | 1 | 2024 | 22176 | 0.070 |
Why?
|
Radioactive Fallout | 1 | 2005 | 7 | 0.070 |
Why?
|
Health Status | 1 | 2019 | 4077 | 0.070 |
Why?
|
Fibrinolytic Agents | 1 | 2016 | 2084 | 0.070 |
Why?
|
Cohort Studies | 2 | 2019 | 41495 | 0.060 |
Why?
|
Chronic Disease | 1 | 2021 | 9319 | 0.060 |
Why?
|
Nuclear Warfare | 1 | 2005 | 30 | 0.060 |
Why?
|
Defibrillators | 1 | 2005 | 39 | 0.060 |
Why?
|
Aged, 80 and over | 5 | 2024 | 58984 | 0.060 |
Why?
|
Heart Diseases | 1 | 2018 | 2781 | 0.060 |
Why?
|
Adult | 10 | 2023 | 221210 | 0.060 |
Why?
|
Biopsy | 1 | 2017 | 6766 | 0.060 |
Why?
|
Prospective Studies | 6 | 2023 | 54423 | 0.060 |
Why?
|
Cross-Sectional Studies | 2 | 2024 | 26129 | 0.060 |
Why?
|
Internal Medicine | 1 | 2011 | 1051 | 0.060 |
Why?
|
Minnesota | 1 | 2024 | 338 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 1 | 2018 | 3206 | 0.060 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 12973 | 0.060 |
Why?
|
Sodium-Glucose Transporter 2 | 1 | 2023 | 89 | 0.050 |
Why?
|
Emergency Service, Hospital | 2 | 2018 | 7879 | 0.050 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 15266 | 0.050 |
Why?
|
Lecithins | 1 | 2022 | 17 | 0.050 |
Why?
|
Terrorism | 1 | 2005 | 211 | 0.050 |
Why?
|
Sterol O-Acyltransferase | 1 | 2022 | 28 | 0.050 |
Why?
|
Survival Analysis | 1 | 2015 | 10090 | 0.050 |
Why?
|
Hypertension | 1 | 2022 | 8540 | 0.050 |
Why?
|
Heart Valves | 1 | 2024 | 284 | 0.050 |
Why?
|
Patient Discharge | 1 | 2015 | 3443 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5440 | 0.050 |
Why?
|
Diastole | 1 | 2024 | 782 | 0.050 |
Why?
|
Anti-Obesity Agents | 1 | 2024 | 227 | 0.050 |
Why?
|
Self Efficacy | 1 | 2024 | 638 | 0.040 |
Why?
|
Catheters | 1 | 2023 | 427 | 0.040 |
Why?
|
Pneumocystis carinii | 1 | 2020 | 72 | 0.040 |
Why?
|
Disaster Planning | 1 | 2005 | 557 | 0.040 |
Why?
|
Coma | 1 | 2022 | 484 | 0.040 |
Why?
|
Health Resources | 1 | 2024 | 935 | 0.040 |
Why?
|
Lipoproteins, HDL | 1 | 2022 | 676 | 0.040 |
Why?
|
Interprofessional Relations | 2 | 2015 | 990 | 0.040 |
Why?
|
Angiography | 1 | 2022 | 1595 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2016 | 39106 | 0.040 |
Why?
|
American Heart Association | 1 | 2021 | 1039 | 0.030 |
Why?
|
Body Mass Index | 2 | 2024 | 12953 | 0.030 |
Why?
|
Students, Medical | 1 | 2009 | 1936 | 0.030 |
Why?
|
Shock | 1 | 2018 | 314 | 0.030 |
Why?
|
Sex Factors | 2 | 2024 | 10554 | 0.030 |
Why?
|
Coronary Artery Disease | 1 | 2014 | 6403 | 0.030 |
Why?
|
Animals | 3 | 2018 | 168475 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2020 | 2571 | 0.030 |
Why?
|
Cholesterol | 1 | 2022 | 2905 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2024 | 14608 | 0.030 |
Why?
|
Family | 1 | 2023 | 3195 | 0.030 |
Why?
|
Obesity | 2 | 2024 | 12947 | 0.020 |
Why?
|
Organizational Culture | 1 | 2015 | 509 | 0.020 |
Why?
|
Glycopeptides | 1 | 2012 | 220 | 0.020 |
Why?
|
Length of Stay | 1 | 2024 | 6426 | 0.020 |
Why?
|
Self-Help Groups | 1 | 2011 | 192 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 2011 | 1625 | 0.020 |
Why?
|
Peroxidase | 1 | 2012 | 609 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 558 | 0.020 |
Why?
|
Kidney | 1 | 2023 | 7048 | 0.020 |
Why?
|
Inpatients | 1 | 2019 | 2548 | 0.020 |
Why?
|
Social Perception | 1 | 2011 | 433 | 0.020 |
Why?
|
Personal Satisfaction | 1 | 2011 | 644 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2012 | 1186 | 0.020 |
Why?
|
Boston | 1 | 2019 | 9327 | 0.020 |
Why?
|
Phenotype | 1 | 2024 | 16592 | 0.020 |
Why?
|
Motivation | 1 | 2015 | 2006 | 0.020 |
Why?
|
Patient Readmission | 1 | 2019 | 3271 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2011 | 1814 | 0.020 |
Why?
|
Qualitative Research | 1 | 2015 | 3025 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2011 | 2696 | 0.010 |
Why?
|
Dyslipidemias | 1 | 2011 | 868 | 0.010 |
Why?
|
Heart Ventricles | 1 | 2016 | 3807 | 0.010 |
Why?
|
Random Allocation | 1 | 2008 | 2395 | 0.010 |
Why?
|
Quality Improvement | 1 | 2018 | 3802 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10766 | 0.010 |
Why?
|
Cholesterol, LDL | 1 | 2011 | 2382 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2008 | 3415 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2011 | 6312 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2012 | 3826 | 0.010 |
Why?
|
Child, Preschool | 1 | 2022 | 42232 | 0.010 |
Why?
|
Infant | 1 | 2021 | 36193 | 0.010 |
Why?
|
Swine | 1 | 2008 | 5915 | 0.010 |
Why?
|
Communication | 1 | 2011 | 3875 | 0.010 |
Why?
|
Biomedical Research | 1 | 2012 | 3429 | 0.010 |
Why?
|
Child | 1 | 2022 | 80158 | 0.010 |
Why?
|
Clinical Competence | 1 | 2009 | 4793 | 0.010 |
Why?
|
Research Design | 1 | 2009 | 6180 | 0.010 |
Why?
|